SEROMYCIN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Seromycin, and when can generic versions of Seromycin launch?
Seromycin is a drug marketed by Cerovene Inc and is included in one NDA.
The generic ingredient in SEROMYCIN is cycloserine. There are seven drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the cycloserine profile page.
Summary for SEROMYCIN
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 2 |
Raw Ingredient (Bulk) Api Vendors: | 130 |
Clinical Trials: | 31 |
Patent Applications: | 4,569 |
Formulation / Manufacturing: | see details |
DailyMed Link: | SEROMYCIN at DailyMed |
Recent Clinical Trials for SEROMYCIN
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
University of Calgary | Phase 2 |
University of Miami | Phase 4 |
Shirley Ryan AbilityLab | Phase 4 |
Anatomical Therapeutic Chemical (ATC) Classes for SEROMYCIN
US Patents and Regulatory Information for SEROMYCIN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cerovene Inc | SEROMYCIN | cycloserine | CAPSULE;ORAL | 060593-001 | Approved Prior to Jan 1, 1982 | RX | No | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |